Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 2
1992 1
1993 1
1994 2
1995 2
1997 3
1998 1
1999 2
2000 4
2001 8
2002 8
2003 4
2004 7
2005 7
2006 14
2007 8
2008 5
2009 3
2010 10
2011 11
2012 8
2013 11
2014 11
2015 10
2016 11
2017 15
2018 6
2019 22
2020 20
2021 41
2022 45
2023 18

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Results by year

Filters applied: . Clear all
Page 1
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team; Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS. Wrapp D, et al. Among authors: pohlmann s. Cell. 2020 May 28;181(5):1004-1015.e15. doi: 10.1016/j.cell.2020.04.031. Epub 2020 May 5. Cell. 2020. PMID: 32375025 Free PMC article.
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.
Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck HM, Pöhlmann S, Hoffmann M. Arora P, et al. Among authors: pohlmann s. Lancet Infect Dis. 2023 Jan;23(1):22-23. doi: 10.1016/S1473-3099(22)00733-2. Epub 2022 Nov 18. Lancet Infect Dis. 2023. PMID: 36410372 Free PMC article. No abstract available.
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Pöhlmann S. Hoffmann M, et al. Among authors: pohlmann s. Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24. Cell. 2022. PMID: 35026151 Free PMC article.
How SARS-CoV-2 makes the cut.
Hoffmann M, Pöhlmann S. Hoffmann M, et al. Among authors: pohlmann s. Nat Microbiol. 2021 Jul;6(7):828-829. doi: 10.1038/s41564-021-00931-x. Nat Microbiol. 2021. PMID: 34194035 No abstract available.
Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1.
Hoffmann M, Pöhlmann S. Hoffmann M, et al. Among authors: pohlmann s. Cell Res. 2022 Jan;32(1):1-2. doi: 10.1038/s41422-021-00603-9. Cell Res. 2022. PMID: 34903854 Free PMC article. No abstract available.
Mutation D614G increases SARS-CoV-2 transmission.
Arora P, Pöhlmann S, Hoffmann M. Arora P, et al. Among authors: pohlmann s. Signal Transduct Target Ther. 2021 Mar 1;6(1):101. doi: 10.1038/s41392-021-00502-w. Signal Transduct Target Ther. 2021. PMID: 33649299 Free PMC article. No abstract available.
Dalbavancin: novel candidate for COVID-19 treatment.
Hoffmann M, Jin Y, Pöhlmann S. Hoffmann M, et al. Among authors: pohlmann s. Cell Res. 2021 Mar;31(3):243-244. doi: 10.1038/s41422-020-00459-5. Cell Res. 2021. PMID: 33473156 Free PMC article. No abstract available.
Cellular entry of the SARS coronavirus.
Hofmann H, Pöhlmann S. Hofmann H, et al. Among authors: pohlmann s. Trends Microbiol. 2004 Oct;12(10):466-72. doi: 10.1016/j.tim.2004.08.008. Trends Microbiol. 2004. PMID: 15381196 Free PMC article. Review.
303 results